Do you have an idea for a new therapeutic indication using Bayer compounds?
Bayer is supporting the exploration of new indications by offering grants and further financial support.
Submission ends September 30, 2017
We are offering financial support for specific non-clinical or clinical research projects to evaluate a Bayer compound in a new indication, i.e. an indication outside those currently approved or in clinical trials.
Join our efforts and expertise in a mechanism-based approach in which we potentially support your project idea, both financially and with respective compounds.
Inhibition of cyclooxygenases
Inhibition of the Aldo-keto reductase family 1 member C3
Inhibition of the Alpha 2c adrenergic receptor
Inhibition of chymase
Inhibition of bacterial gyrase
Inhibition of PI3 Kinase-αlpha and delta
Antagonism at the prostaglandin EP4 receptor
Antagonism at the mineralocorticoid receptor
Interferon beta 1b
Stabilizer of the hypoxia-induced factor (HIF) / Inhibition of HIF-PH (hypoxia-induced factor prolyl hydroxylases)
Anti-infective, mainly used for worm infections
Calcium channel blocker
Inhibition of the purinergic receptor P2X3
Inhibition of FGF receptors
Partial agonism at the Adenosin A1 receptor
Inhibition of the (inducible) Prostaglandin E synthase
Stimulation of the soluble guanylat cyclase
Modulation of the progesterone receptor
If you are successful in the first stage, you will be invited to develop and send your detailed full study proposal and will receive a grant of up to 5,000€* for this purpose.
For more details, see How it works below.
*If in accordance with your local laws and compliance regulations; to be paid to your institution/employer after acceptance of the grant conditions.
If successful in the next round, you can receive further funding to conduct your preclinical or clinical study under an Investigator-Initiated Research (IIR) agreement, subject to negotiation and according to fair market value.
We will also provide you with the Bayer compound you need for your research in sufficient quantities and formulations.
**The terms and conditions of such a contract will include a consideration to Bayer for the financial support of the study. In general, the applicant will become owner of the results of the studies, yet with certain licenses and license options to Bayer, to be negotiated.
Deadline September 30, 2017
In a first step, please submit a short proposal (max. 1,500 words / 2 pages) of the research you intend to do, indicating the Bayer compound and the new therapeutic indication you plan to target with it.
For more details on what to include, see Submission.
To submit, you will be redirected to the Bayer SIRIUS online submission platform, where you have to register first.
Please note that any information that you submit is non-confidential.
8 - 10 weeks after submission deadline
Of the submitted short proposals, depending on the number of suitable applications, up to 12 projects will be selected by a dedicated Bayer-internal Grants4Indications Review Committee.
The selected projects will then be invited to submit a full study proposal. Usually, applicants will receive notification on whether their project was selected within 8 weeks.
The proposals will be reviewed by experienced scientists at Bayer from different functions. Pre-defined criteria are e.g.:
The decision as to whether Bayer invites for submission will be made at the sole discretion of Bayer.
Within 4 weeks after invitation
If invited, please prepare and hand in a detailed non-confidential study protocol.
Upon receipt of this full proposal, the grant of up to 5000€ will be paid out to your employer or institution (if in accordance with your local laws and compliance regulations).
Please include the following information in your full study proposal (approximately 10-15 pages):
Please also submit your full study proposal through the SIRIUS submission platform.
The submitted detailed study protocols will again be reviewed and scored. The Bayer-internal Grants4Indications™ Review Committee will then, according to the overall rating, select those projects that Bayer is interested in funding.
The funding of such studies will be subject to a contract between applicant and Bayer, which will be negotiated upon notification to the applicant that Bayer intends to pursue the proposed research.
The decision as to whether Bayer enters into an agreement under which Bayer provides further support will be made at the sole discretion of Bayer.
Please describe the new therapeutic indication you plan to target
In addition, we’d like to receive a copy of your CV and any necessary publications relevant to your research.
Your short proposal should be max. 1500 words / 2 pages. Please bear in mind that all the information provided has to be non-confidential to allow a first evaluation of the proposal.
To submit, you will be redirected to the Bayer SIRIUS online submission platform, where you might have to register first if you don't have an account yet.
Many medications have originally been developed for a completely different indication. Only later, completely new indications have been identified which in many cases, were even more successful than the original one.
Originally developed as a drug against pain and fever, Aspirin is now approved for primary and secondary prevention of cardiovascular events in certain countries due to its effect as a platelet aggregation inhibitor.
Bayer provides grants for targets/biomarkers and offers expertise, tools and technologies to help develop your ideas.
Bayer offers grants for the development of innovative app projects contributing to improve health outcomes or pharmaceutical processes.
Bayer offers financial support to evaluate your antibody or derivate and to promote its exploration for a potential new drug development.